1. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. Jama. 2016;316(12):1289-97.
2. Bogden PE, Koontz LM, Williamson P, Abbott RD. The physician and pharmacist team: An effective approach to cholesterol reduction. J Gen Intern Med. 1997;12(3):158-64.
3. Kellick KA, Burns K, McAndrew E, Haberl E, Hook N, Ellis A. Outcome monitoring of fluvastatin in a department of veterans affairs lipid clinic. The American journal of cardiology. 1995;76(1-2):62A-4A.
4. Konzem SL, Gray DR, Kashyap ML. Effect of pharmaceutical care on optimum colestipol treatment in elderly hypercholesterolemic veterans. Pharmacotherapy. 1997;17(3):576-83.
5. O'Donnell DC, Chen NT, Piziak VK. Goal attainment and maintenance of serum cholesterol level in a pharmacist-coordinated lipid clinic. Am J Health Syst Pharm. 2001;58(4):325-30.
6. Birtcher KK, Greisinger AJ, Brehm BJ, Wehmanen OA, Furman LM, Salinas CC, et al. A secondary prevention lipid clinic reaches low-density lipoprotein cholesterol goals more often than usual cardiology care with coronary heart disease. J Clin Lipidol. 2010;4(1):46-52.
7. Shaffer J, Wexler LF. Reducing Low-Density Lipoprotein Cholesterol Levels in an Ambulatory Care System: Results of a Multidisciplinary Collaborative Practice Lipid Clinic Compared With Traditional Physician-Based Care. Arch Intern Med. 1995;155(21):2330-5.
8. Mazzolini TA, Irons BK, Schell EC, Seifert CF. Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA Medical Centers. J Manag Care Pharm. 2005;11(9):763-71.
9. Liebeskind A, Warden BA, Sikand G, Duell PB, Guyton JR. JCL Roundtable: Lipid clinic operations. J Clin Lipidol. 2019;13(4):511-21.
10. Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC, et al. RE-AIM Planning and Evaluation Framework: Adapting to New Science and Practice With a 20-Year Review. Frontiers in Public Health. 2019;7(64).
11. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89.
12. Psek W, Davis FD, Gerrity G, Stametz R, Bailey-Davis L, Henninger D, et al. Leadership Perspectives on Operationalizing the Learning Health Care System in an Integrated Delivery System. eGEMs. 2016;4(3):1233.
13. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;139(25):e1082-e143.
14. Proctor EK, Powell BJ, McMillen JC. Implementation strategies: recommendations for specifying and reporting. Implement Sci. 2013;8:139.
15. Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC. RE-AIM Planning and evaluation framework: adapting to new science and practice with a 20-year review. Front Public Health. 2019;7.
16. King DK, Glasgow RE, Leeman-Castillo B. Reaiming RE-AIM: using the model to plan, implement, and evaluate the effects of environmental change approaches to enhancing population health. American journal of public health. 2010;100(11):2076-84.
17. Lobb R, Colditz GA. Implementation science and its application to population health. Annual review of public health. 2013;34:235-51.
18. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81.
19. Harris DE, Record NB, Gipson GW, Pearson TA. Lipid lowering in a multidisciplinary clinic compared with primary physician management. American Journal of Cardiology. 1998;81(7):929-33.
20. Harris DE, Record NB, Gipson GW, Pearson TA. Lipid lowering in a multidisciplinary clinic compared with primary physician management. The American Journal of Cardiology. 1998;81(7):929-33.
21. Birtcher KK, Bowden C, Ballantyne CM, Huyen M. Strategies for implementing lipid-lowering therapy: Pharmacy-based approach. American Journal of Cardiology. 2000;85(3 SUPPL. 1):30-5.
22. Glasgow RE, Chambers D. Developing robust, sustainable, implementation systems using rigorous, rapid and relevant science. Clin Transl Sci. 2012;5(1):48-55.
23. Nhim K, Gruss SM, Porterfield DS, Jacobs S, Elkins W, Luman ET, et al. Using a RE-AIM framework to identify promising practices in National Diabetes Prevention Program implementation. Implement Sci. 2019;14(1):81.
24. Tabak RG, Khoong EC, Chambers DA, Brownson RC. Bridging research and practice: models for dissemination and implementation research. Am J Prev Med. 2012;43(3):337-50.
25. Nilsen P. Making sense of implementation theories, models and frameworks. Implement Sci. 2015;10:53.